| Today's Rundown Featured Story | By Annalee Armstrong GlaxoSmithKline has successfully overtaken the shingles vaccine market once owned by Merck, but enter king Pfizer. The Big Pharma juggernaut has signed a third deal with COVID-19 vaccine partner BioNTech, this time to develop an mRNA-based shingles vaccine, in a deal worth $225 million upfront to BioNtech. read more |
| |
|---|
|
Top Stories By Annalee Armstrong Merck KGaA is taking a fourth option in its deal with bispecific immunotherapy biotech F-Star Therapeutics, which has attracted the eyes of a who’s who of Big Pharma. The latest Merck option will bring the total due to F-Star up to $765 million in milestone-based revenue payments. read more By Eric Sagonowsky Spectrum Pharmaceuticals has weathered changes and challenges in recent years, including a sale of its marketed drugs portfolio in 2019 and an FDA rejection for a key prospect last year. Now, it's cutting staff to save cash and focus on its important cancer meds. read more By Kyle LaHucik Avrobio already trimmed expectations for its Fabry disease gene therapy in May because of Sanofi's Fabrazyme approval, and now the biotech is axing it all together. read more By Nick Paul Taylor SalioGen Therapeutics is moving quickly. Ten months after exiting stealth with $20 million in series A funds, the Massachusetts-based biotech has raised another $115 million to fund its vision of the future of genetic medicines. read more By Kyle LaHucik Applied Therapeutics is pumping the brakes on requesting FDA approval for its first drug after the agency requested clinical outcomes data on the treatment's impact in a rare metabolic disease. read more By Nick Paul Taylor Intellia Therapeutics has found a new CAR-T use for its CRISPR/Cas9 platform: autoimmune diseases. By teaming up with Kyverna Therapeutics, Intellia has secured an option on an allogeneic anti-CD19 CAR-T based on a construct from the lab that discovered Yescarta. read more By Angus Liu Chemotherapy and radiation kill cancer cells by inducing significant DNA damage beyond repair. But some tumors still develop alternative ways to survive. Now, scientists have identified such a molecular pathway that helps cancer cells evade destruction. read more By Conor Hale Thermo Fisher Scientific started off the new year with a new member to its family, closing a $1.85 billion acquisition to build out its recombinant protein catalog. read more By Kevin Dunleavy Pharma companies that said they would cut off campaign funds to those in Congress who fomented the Jan. 6 riots by voting against certifying the presidential election results have quickly changed their stance, according to a report by Accountable.U.S. Merck, Eli Lilly, Pfizer and Johnson & Johnson were cited by the watchdog group. read more By Robert King AbbVie became the third drugmaker in recent months to impose restrictions on sales of 340B-discounted products to covered entities' contract pharmacies. read more | 
| Webinar: A Collaborative Approach to Complex Chemistry Wednesday, January 12, 2022 | 11am ET / 8am PT Complex therapeutics demand complex chemistry expertise. Discover how the right partner can help you overcome complex chemistry challenges through extensive experience, specialised technologies, and true scientific collaboration. Register now. |
Resources Sponsored by: Thermo Fisher Scientific Learn how a CDMO partnered with Thermo Fisher Scientific to manage high-volume process liquid and buffer preparation scale-up. Download the free case study from Thermo Fisher Scientific Sponsored by: Thermo Fisher Scientific A variety of genetic analysis methods are valuable in ensuring that ex vivo human cells to be used for cell-based therapies are correctly identified, have the correct characteristics, and are free of contaminants. Sponsored by: IQVIA Learn how to elevate your omnichannel marketing strategy with Next Best - a combination of data and analytics, deployed to facilitate decision making. Sponsored by: Catalent Biologics Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Thermo Fisher Scientific Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific Sponsored by: Box Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization. Fierce JPM Week 2022 January 18-20, 2022 | Virtual Event Fierce Drug Safety Summit February 8-9, 2022 | Arlington, VA Fierce BD&L Summit for Life Sciences March 2022 | San Francisco, CA Fierce Promotional Review Committee Compliance and Best Practices Summit April 12-14, 2022 | New Brunswick, NJ Fierce Medical Affairs Strategic Summit (MASS) East April 12-14, 2022 | New Brunswick, NJ Fierce Health IT Summit April 20, 2022 | Virtual Event Fierce Trial Master File Summit May 2022 | Location TBD Fierce Digital Pharma Innovation Week June 2022 | Virtual Event Fierce Biotech Next-Gen June 29, 2022 | Virtual Event Fierce Pharma PR & Communications Summit July 2022 | Location TBD (NYC Metro Area) Fierce Biotech Forum October 2022 | Location TBD Fierce Biotech Virtual Forum October 19, 2022 | Virtual Event Fierce Pharma Meeting Professionals Summit November 2-3, 2022 | Atlantic City, NJ Fierce European Trial Master File Summit November 2022 | Location TBD | 
